0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessThis trial met its primary objective, regorafenib significantly delayed disease progression after first-line treatment in advanced non-adipocytic STS. This was associated with a non-significant trend of overall survival improvement.
Nicolas Penel, Antoîne Italiano, Jennifer Wallet, L. Chaigneau, B. Verret, Nelly Firmin, Sarah Watson, Thibaud Valentin, Emmanuelle Bompas, François Bertucci, Mehdi Brahmi, Clémence Hénon, Angélique Brunot, Mariella Spalato Ceruso, Marie Vanseymortier, E Heyman-Decoupigny, Thomas Ryckewaert, Marie‐Cécile Le Deley, Christophe Perrin, Jean Yves Blay (2025). Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial. , 36(8), DOI: https://doi.org/10.1016/j.annonc.2025.03.024.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2025
Authors
20
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.annonc.2025.03.024
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
